Director, Clinical Development

Remote, South Africa

About Us Join us in helping patients with rare diseases. At Egetis Therapeutics we challenge the status quo for the benefit of those in need. We offer an open, positive and supportive culture where everyone can be their best. Through trust, we work seamlessly across functions. As an employee you are empowered and encouraged to have an entrepreneurial spirit, enjoying an organization with conscious and efficient decision-making and we take pride in our collaborative working environment! In February 2025, the European Commission approved Egetis’ Emcitate® (tiratricol) as the first and only treatment of peripheral thyrotoxicosis in patients with monocarboxylate transporter 8 (MCT8) deficiency (Allan-Herndon-Dudley syndrome). In March 2026, the U.S. FDA accepted the filing of Egetis’ New Drug Application (NDA) for Emcitate® (tiratricol) for the treatment of MCT8 deficiency and granted Priority Review. The Prescription Drug User Fee Act (PDUFA) target action date is September 28, 2026. As a courageous, committed, and collaborative organization, we are seeking to grow our team to drive success both in the pre-launch and post launch phases. For more information, please visit our website...